Melanoma redox biology and the emergence of drug resistance.

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI:10.1016/bs.acr.2024.06.004
Therese Featherston, Martina Paumann-Page, Mark B Hampton
{"title":"Melanoma redox biology and the emergence of drug resistance.","authors":"Therese Featherston, Martina Paumann-Page, Mark B Hampton","doi":"10.1016/bs.acr.2024.06.004","DOIUrl":null,"url":null,"abstract":"<p><p>Melanoma is the deadliest form of skin cancer, with the loss of approximately 60,000 lives world-wide each year. Despite the development of targeted therapeutics, including compounds that have selectivity for mutant oncoproteins expressed only in cancer cells, many patients are either unresponsive to initial therapy or their tumors acquire resistance. This results in five-year survival rates of below 25%. New strategies that either kill drug-resistant melanoma cells or prevent their emergence would be extremely valuable. Melanoma, like other cancers, has long been described as being under increased oxidative stress, resulting in an increased reliance on antioxidant defense systems. Changes in redox homeostasis are most apparent during metastasis and during the metabolic reprogramming associated with the development of treatment resistance. This review discusses oxidative stress in melanoma, with a particular focus on targeting antioxidant pathways to limit the emergence of drug resistant cells.</p>","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.acr.2024.06.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Melanoma is the deadliest form of skin cancer, with the loss of approximately 60,000 lives world-wide each year. Despite the development of targeted therapeutics, including compounds that have selectivity for mutant oncoproteins expressed only in cancer cells, many patients are either unresponsive to initial therapy or their tumors acquire resistance. This results in five-year survival rates of below 25%. New strategies that either kill drug-resistant melanoma cells or prevent their emergence would be extremely valuable. Melanoma, like other cancers, has long been described as being under increased oxidative stress, resulting in an increased reliance on antioxidant defense systems. Changes in redox homeostasis are most apparent during metastasis and during the metabolic reprogramming associated with the development of treatment resistance. This review discusses oxidative stress in melanoma, with a particular focus on targeting antioxidant pathways to limit the emergence of drug resistant cells.

黑色素瘤氧化还原生物学和耐药性的出现。
黑色素瘤是最致命的皮肤癌,全世界每年约有 60,000 人因此丧生。尽管开发出了靶向治疗药物,包括对只在癌细胞中表达的突变肿瘤蛋白具有选择性的化合物,但许多患者要么对初始治疗无反应,要么肿瘤产生抗药性。这导致五年生存率低于 25%。能够杀死耐药黑色素瘤细胞或防止其出现的新策略将极具价值。黑色素瘤与其他癌症一样,长期以来一直被描述为氧化应激增加,导致对抗氧化防御系统的依赖性增加。氧化还原平衡的变化在转移过程中以及与耐药性发展相关的代谢重编程过程中最为明显。本综述将讨论黑色素瘤中的氧化应激,尤其侧重于靶向抗氧化途径以限制耐药细胞的出现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信